噬菌体展示技术在肿瘤诊断和治疗中的应用

阳艳丽; 王自正

噬菌体展示技术在肿瘤诊断和治疗中的应用

阳艳丽 , 王自正

文章导航 > 国际放射医学核医学杂志 > 2008, 32 > 2: (65-68)

引用本文:

Citation:

噬菌体展示技术在肿瘤诊断和治疗中的应用

阳艳丽¹,
王自正²

1. 210009 南京, 东南大学医学院临床检验诊断学;
2. 210006 南京, 南京医科大学附属南京第一医院临床核医学
基金项目:
江苏省社会发展科技项目(BS2004507)

Application of phage display in diagnosis and therapy of cancer

YANG Yan-li¹,
WANG Zi-zheng²

1. Clincal Laboretory Diagnostics, Medical College of Southeast University, Nanjing 210009, China;
2. Nanjing Clinical Nuclear Medicine Center, Nanjing First Hospital, Nanjing Medical University, Nanjing 210006, China

摘要: 噬菌体体内展示技术的出现,使器官靶向性多肽的筛选、器官特异性血管分子作图成为可能。更值得注意的是,通过动物体内的筛选,鉴定出了一系列肿瘤相关分子的标志物的特异性多肽配体,为肿瘤的诊断,肿瘤药物的输送以及肿瘤血管性基因治疗等提供了靶向性分子。最近,人们又成功地将此技术应用于肿瘤患者,并鉴定出与肿瘤特异性结合的多肽模序。
- 肽库 /
- 药物筛选试验,抗肿瘤 /
- 分子诊断技术 /
- 肿瘤辅助疗法 /
- 噬菌体展示
Abstract: Phage display is possible to screening targeted peptides, mapping organ-specific vascular molecule because of in viva phage display. It is more remarkable that a variety of peptide ligands specific for tumor-associated makers is identified, which supplied targeted molecules for tumor diagnosis, delivery of tumor drugs and tumor vascular gene therapy. Recently, people succeed in applying the technology to tumor patients and identifying peptide motifs binding to tumor specifically.
- Peptide library /
- Drug screening assays,antitumor /
- Molecular diagnostic techniques /
- Neoadjuvant therapy /
- Phage display
本作品遵循Signature-Non-Commercial Use 4.0 International (CC BY-NC 4.0)协议

[1]	Hassan ME, Highsmith EW. Phage display technology:clinical applications and recent innovations[J]. Clin Biochem, 2002, 35(6):425-445.
[2]	Mori T. Cancer-specificligandsidentified from screening of peptidedisplay libraries[J]. Curr Pharm Des, 2004, 10(19):2335-2343.
[3]	Zitzmann S, Mier W, Schad A, et al. A new prostate carcinoma binding peptide (DUP-1) for tumor imaging and therapy[J]. Clin Cancer Res, 2005, 11(1):139-146.
[4]	Weller EG, Wong MK, Modzelewsk RA, et al. Ultrasonic imaging of tumor angiogenesis using contrast mierobubbles targeted via the tumor-binding peptide arginine-arginine-leucine[J]. Cancer Res,2005, 65(2):533-539.
[5]	Valadon P, Garnett JD, Testa JE, et al. Screening phage display libraries for organ-specific vascular immunotargeting in vivo[J]. Proc Natl Acad Sci USA, 2006, 103(2):407-412.
[6]	Hoffman JA, Giraudo E, SinghM, et al. Progressive vascular changes in a transgenic mouse model of squamous cell carcinoma[J]. Cancer Cell, 2003, 4(5):383-391.
[7]	Joyce JA, Laakkonen P, Bernasconi M, et al. Stage-specific vascular markers revealed by phage display in a mouse model of pancreatic islet tumorigenesis[J]. Cancer Cell, 2003, 4(5):393-403.
[8]	Barth S, Huhn M, Matthey B, et al. Ki-4(scFv)-ETA, a new recombinant anti-CD30 immunotoxin with highly specific cytotoxic activity against disseminated Hodgkin tumors in SCID mice[J]. Blood, 2000, 95(12):3909-3914.
[9]	Adams GP, Shaller CC, Dadachova E, et al. A single treatment of Yttrium-90-1abeled CHX-A"-C6.5 diabody inhibits the growth of established human tumor xenografts in immunodeficient mice[J]. Cancer Res, 2004, 64(17):6200-6206.
[10]	Asano R, Sone Y, Makabe K, et al. Humanization of the bispeeifie epidermal growth factor receptor x CD3 diabody and its efficacy as a potential clinical reagent[J]. Clin Cancer Res, 2006, 12(13):4036-4042.
[11]	Kerbel R, Folkman J. Clinical translation of angiogenesis inhibitors[J]. Nat Rev Cancer, 2002, 2(10):727-739.
[12]	Curnis F, Sacchi A, Borgna L, et al. Enhancement of tumor necrosis factor alpha antitumor immunotherapeutic properties by targeted delivery to aminopeptidase N (CD13)[J]. Nat Biotechnol, 2000, 18(11):1185-1190.
[13]	Laakkonen P, Akerman ME, Biliran H, et al. Antitumor activity of a homing peptide that targets tumor lymphatics and tumor eells[J]. Proc Natl Acad Sci USA, 2004, 101(25):9381-9386.
[14]	Larocca D, Baird A. Receptor-mediated gene transfer by phagedisplay vectors:applications in functional genomics and gene therapy[J]. Drug Discov Today, 2001, 6(15):793-801.
[15]	Krag DN, Fulle SP, Oligino L, et al. Phage-displayed random peptide libraries in mice:toxicity after serial panning[J]. Cancer Chemother Pharmacol, 2002, 50(4):325-332.
[16]	Arap W, Kdonin MG, Trepel M, et al. Steps toward mapping the human vasculature by phage display[J]. Nat Med, 2002, 8(2):121-127.
[17]	Krag DN, Shukla GS, Shen GP, et al. Selection of tumor-binding ligands in cancer patients with phage display libraries[J]. Cancer Res, 2006, 66(15):7724-7733.

[1]	俞杨 , 王自正 . 噬菌体展示体内筛选技术及其应用进展. 国际放射医学核医学杂志, 2008, 32(1): 5-8.
[2]	黄斌 , 俞杨 , 王自正 . 噬菌体展示肽库技术在肿瘤诊治研究中的应用. 国际放射医学核医学杂志, 2011, 35(4): 202-206. doi: 10.3760/cma.j.issn.1673-4114.2011.04.002
[3]	刘金剑 , 刘鉴峰 , 孟爱民 . 噬菌体展示技术在分子核医学中的应用. 国际放射医学核医学杂志, 2013, 37(6): 352-354,373. doi: 10.3760/cma.j.issn.1673-4114.2013.06.007
[4]	褚丽萍 , 王彦 , 王月英 , 刘金剑 , 吴红英 , 刘鉴峰 . 多肽类肺癌显像剂的制备及其初步鉴定. 国际放射医学核医学杂志, 2010, 34(3): 135-138. doi: 10.3760/cma.j.issn.1673-4114.2010.03.002
[5]	董佳佳 , 章斌 . 多种影像学方法评价乳腺癌新辅助化疗疗效的价值比较. 国际放射医学核医学杂志, 2014, 38(6): 427-432. doi: 10.3760/cma.j.issn.1673-4114.2014.06.018
[6]	涂少华 , 陶嵘 , 沈江帆 . 单克隆抗体人源化技术研究进展. 国际放射医学核医学杂志, 2014, 38(5): 328-331. doi: 10.3760/cma.j.issn.1673-4114.2014.05.012
[7]	王金玉 , 武兆忠 . 反义寡脱氧核苷酸技术在分子影像中的应用. 国际放射医学核医学杂志, 2009, 33(1): 1-5. doi: 10.3760/cma.j.issn.1673-4114.2009.01.001
[8]	常伟 , 高再荣 . 甲状腺癌分子影像诊断与靶向治疗研究进展. 国际放射医学核医学杂志, 2009, 33(4): 218-221. doi: 10.3760/cma.j.issn.1673-4114.2009.04.008
[9]	李天然 , 田嘉禾 . 功能与分子影像学的内涵与范畴. 国际放射医学核医学杂志, 2007, 31(4): 193-196.
[10]	李天然 , 田嘉禾 . 小动物PET及PET-CT及其在分子影像学中的应用. 国际放射医学核医学杂志, 2008, 32(1): 1-4.

点击查看大图

计量

文章访问数: 1442
HTML全文浏览量: 85
PDF下载量: 2

噬菌体展示技术在肿瘤诊断和治疗中的应用

阳艳丽¹
王自正²

1. 210009 南京, 东南大学医学院临床检验诊断学;
2. 210006 南京, 南京医科大学附属南京第一医院临床核医学

收稿日期: 2007-07-16

基金项目: 江苏省社会发展科技项目(BS2004507)

关键词:

摘要: 噬菌体体内展示技术的出现,使器官靶向性多肽的筛选、器官特异性血管分子作图成为可能。更值得注意的是,通过动物体内的筛选,鉴定出了一系列肿瘤相关分子的标志物的特异性多肽配体,为肿瘤的诊断,肿瘤药物的输送以及肿瘤血管性基因治疗等提供了靶向性分子。最近,人们又成功地将此技术应用于肿瘤患者,并鉴定出与肿瘤特异性结合的多肽模序。